222 related articles for article (PubMed ID: 29093152)
1. Pomalidomide in Patients with Interstitial Lung Disease due to Systemic Sclerosis: A Phase II, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study.
Hsu VM; Denton CP; Domsic RT; Furst DE; Rischmueller M; Stanislav M; Steen VD; Distler JHW; Korish S; Cooper A; Choi S; Schafer PH; Horan G; Hough DR
J Rheumatol; 2018 Mar; 45(3):405-410. PubMed ID: 29093152
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of pirfenidone in systemic sclerosis-related interstitial lung disease-a randomised controlled trial.
Acharya N; Sharma SK; Mishra D; Dhooria S; Dhir V; Jain S
Rheumatol Int; 2020 May; 40(5):703-710. PubMed ID: 32239322
[TBL] [Abstract][Full Text] [Related]
3. Effect of mycophenolate mofetil (MMF) on systemic sclerosis-related interstitial lung disease with mildly impaired lung function: a double-blind, placebo-controlled, randomized trial.
Naidu GSRSNK; Sharma SK; Adarsh MB; Dhir V; Sinha A; Dhooria S; Jain S
Rheumatol Int; 2020 Feb; 40(2):207-216. PubMed ID: 31813058
[TBL] [Abstract][Full Text] [Related]
4. Effects and safety of rituximab in systemic sclerosis: an analysis from the European Scleroderma Trial and Research (EUSTAR) group.
Jordan S; Distler JH; Maurer B; Huscher D; van Laar JM; Allanore Y; Distler O;
Ann Rheum Dis; 2015 Jun; 74(6):1188-94. PubMed ID: 24442885
[TBL] [Abstract][Full Text] [Related]
5. Nintedanib for Systemic Sclerosis-Associated Interstitial Lung Disease.
Distler O; Highland KB; Gahlemann M; Azuma A; Fischer A; Mayes MD; Raghu G; Sauter W; Girard M; Alves M; Clerisme-Beaty E; Stowasser S; Tetzlaff K; Kuwana M; Maher TM;
N Engl J Med; 2019 Jun; 380(26):2518-2528. PubMed ID: 31112379
[TBL] [Abstract][Full Text] [Related]
6. Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial.
Tashkin DP; Roth MD; Clements PJ; Furst DE; Khanna D; Kleerup EC; Goldin J; Arriola E; Volkmann ER; Kafaja S; Silver R; Steen V; Strange C; Wise R; Wigley F; Mayes M; Riley DJ; Hussain S; Assassi S; Hsu VM; Patel B; Phillips K; Martinez F; Golden J; Connolly MK; Varga J; Dematte J; Hinchcliff ME; Fischer A; Swigris J; Meehan R; Theodore A; Simms R; Volkov S; Schraufnagel DE; Scholand MB; Frech T; Molitor JA; Highland K; Read CA; Fritzler MJ; Kim GHJ; Tseng CH; Elashoff RM;
Lancet Respir Med; 2016 Sep; 4(9):708-719. PubMed ID: 27469583
[TBL] [Abstract][Full Text] [Related]
7. Design of a randomised, placebo-controlled clinical trial of nintedanib in patients with systemic sclerosis-associated interstitial lung disease (SENSCIS™).
Distler O; Brown KK; Distler JHW; Assassi S; Maher TM; Cottin V; Varga J; Coeck C; Gahlemann M; Sauter W; Schmidt H; Highland KB;
Clin Exp Rheumatol; 2017; 35 Suppl 106(4):75-81. PubMed ID: 28664834
[TBL] [Abstract][Full Text] [Related]
8. Nintedanib in Patients With Systemic Sclerosis-Associated Interstitial Lung Disease: Subgroup Analyses by Autoantibody Status and Modified Rodnan Skin Thickness Score.
Kuwana M; Allanore Y; Denton CP; Distler JHW; Steen V; Khanna D; Matucci-Cerinic M; Mayes MD; Volkmann ER; Miede C; Gahlemann M; Quaresma M; Alves M; Distler O
Arthritis Rheumatol; 2022 Mar; 74(3):518-526. PubMed ID: 34514739
[TBL] [Abstract][Full Text] [Related]
9. Long-Term Safety and Efficacy of Tocilizumab in Early Systemic Sclerosis-Interstitial Lung Disease: Open-Label Extension of a Phase 3 Randomized Controlled Trial.
Khanna D; Lin CJF; Furst DE; Wagner B; Zucchetto M; Raghu G; Martinez FJ; Goldin J; Siegel J; Denton CP
Am J Respir Crit Care Med; 2022 Mar; 205(6):674-684. PubMed ID: 34851799
[No Abstract] [Full Text] [Related]
10. STRATUS: A Phase II Study of Abituzumab in Patients With Systemic Sclerosis-associated Interstitial Lung Disease.
Khanna D; Tashkin DP; Wells AU; Seibold JR; Wax S; Vazquez-Mateo C; Fleuranceau-Morel P; Damian D; Denton CP
J Rheumatol; 2021 Aug; 48(8):1295-1298. PubMed ID: 33004536
[TBL] [Abstract][Full Text] [Related]
11. A one-year, phase I/IIa, open-label pilot trial of imatinib mesylate in the treatment of systemic sclerosis-associated active interstitial lung disease.
Khanna D; Saggar R; Mayes MD; Abtin F; Clements PJ; Maranian P; Assassi S; Saggar R; Singh RR; Furst DE
Arthritis Rheum; 2011 Nov; 63(11):3540-6. PubMed ID: 21769849
[TBL] [Abstract][Full Text] [Related]
12. Effect of Nintedanib on Lung Function in Patients With Systemic Sclerosis-Associated Interstitial Lung Disease: Further Analyses of a Randomized, Double-Blind, Placebo-Controlled Trial.
Maher TM; Mayes MD; Kreuter M; Volkmann ER; Aringer M; Castellvi I; Cutolo M; Stock C; Schoof N; Alves M; Raghu G;
Arthritis Rheumatol; 2021 Apr; 73(4):671-676. PubMed ID: 33142016
[TBL] [Abstract][Full Text] [Related]
13. Predicting treatment outcomes and responder subsets in scleroderma-related interstitial lung disease.
Roth MD; Tseng CH; Clements PJ; Furst DE; Tashkin DP; Goldin JG; Khanna D; Kleerup EC; Li N; Elashoff D; Elashoff RM;
Arthritis Rheum; 2011 Sep; 63(9):2797-808. PubMed ID: 21547897
[TBL] [Abstract][Full Text] [Related]
14. Effect of nintedanib in patients with systemic sclerosis-associated interstitial lung disease and risk factors for rapid progression.
Khanna D; Maher TM; Volkmann ER; Allanore Y; Smith V; Assassi S; Kreuter M; Hoffmann-Vold AM; Kuwana M; Stock C; Alves M; Sambevski S; Denton CP
RMD Open; 2023 Feb; 9(1):. PubMed ID: 36796874
[TBL] [Abstract][Full Text] [Related]
15. An Open-label, Phase II Study of the Safety and Tolerability of Pirfenidone in Patients with Scleroderma-associated Interstitial Lung Disease: the LOTUSS Trial.
Khanna D; Albera C; Fischer A; Khalidi N; Raghu G; Chung L; Chen D; Schiopu E; Tagliaferri M; Seibold JR; Gorina E
J Rheumatol; 2016 Sep; 43(9):1672-9. PubMed ID: 27370878
[TBL] [Abstract][Full Text] [Related]
16. Intravenous cyclophosphamide vs rituximab for the treatment of early diffuse scleroderma lung disease: open label, randomized, controlled trial.
Sircar G; Goswami RP; Sircar D; Ghosh A; Ghosh P
Rheumatology (Oxford); 2018 Dec; 57(12):2106-2113. PubMed ID: 30053212
[TBL] [Abstract][Full Text] [Related]
17. Safety and efficacy of subcutaneous tocilizumab in systemic sclerosis: results from the open-label period of a phase II randomised controlled trial (faSScinate).
Khanna D; Denton CP; Lin CJF; van Laar JM; Frech TM; Anderson ME; Baron M; Chung L; Fierlbeck G; Lakshminarayanan S; Allanore Y; Pope JE; Riemekasten G; Steen V; Müller-Ladner U; Spotswood H; Burke L; Siegel J; Jahreis A; Furst DE
Ann Rheum Dis; 2018 Feb; 77(2):212-220. PubMed ID: 29066464
[TBL] [Abstract][Full Text] [Related]
18. A multicenter, open-label, comparative study of B-cell depletion therapy with Rituximab for systemic sclerosis-associated interstitial lung disease.
Daoussis D; Melissaropoulos K; Sakellaropoulos G; Antonopoulos I; Markatseli TE; Simopoulou T; Georgiou P; Andonopoulos AP; Drosos AA; Sakkas L; Liossis SN
Semin Arthritis Rheum; 2017 Apr; 46(5):625-631. PubMed ID: 27839742
[TBL] [Abstract][Full Text] [Related]
19. RISE-SSc: Riociguat in diffuse cutaneous systemic sclerosis.
Distler O; Pope J; Denton C; Allanore Y; Matucci-Cerinic M; de Oliveira Pena J; Khanna D
Respir Med; 2017 Jan; 122 Suppl 1():S14-S17. PubMed ID: 27746061
[TBL] [Abstract][Full Text] [Related]
20. Long-term follow-up of patients with scleroderma interstitial lung disease treated with intravenous cyclophosphamide pulse therapy: a single-center experience.
Balbir-Gurman A; Yigla M; Guralnik L; Hardak E; Solomonov A; Rozin AP; Toledano K; Dagan A; Bishara R; Markovits D; Nahir MA; Braun-Moscovici Y
Isr Med Assoc J; 2015 Mar; 17(3):150-6. PubMed ID: 25946765
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
